Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes.

Julsgaard M, Hvas CL, Gearry RB, Gibson PR, Fallingborg J, Sparrow MP, Bibby BM, Connell WR, Brown SJ, Kamm MA, Lawrance IC, Vestergaard T, Svenningsen L, Baekdal M, Kammerlander H, Walsh A, Boysen T, Bampton P, Radford-Smith G, Kjeldsen J, Andrews JM, Subramaniam K, Moore GT, Jensen NM, Connor SJ, Wildt S, Wilson B, Ellard K, Christensen LA, Bell SJ.

Inflamm Bowel Dis. 2019 May 29. pii: izz110. doi: 10.1093/ibd/izz110. [Epub ahead of print]

PMID:
31141607
2.

Body Composition Adjusted Dosing of Gemcitabine-Nab-Paclitaxel in Pancreatic Cancer Does Not Predict Toxicity Compared to Body Surface Area Dosing.

Freckelton J, Croagh D, Holt DQ, Fox A, Wong R, Lee M, Moore GT.

Nutr Cancer. 2019;71(4):624-628. doi: 10.1080/01635581.2018.1542011. Epub 2019 Feb 9.

PMID:
30741000
3.

Crohn's & Colitis Australia inflammatory bowel disease audit: measuring the quality of care in Australia.

Massuger W, Moore GTC, Andrews JM, Kilkenny MF, Reyneke M, Knowles S, Purcell L, Alex G, Buckton S, Page AT, Stocks N, Cameron D, Manglaviti F, Pavli P.

Intern Med J. 2019 Jul;49(7):859-866. doi: 10.1111/imj.14187.

PMID:
30525299
4.

Patients' perceptions of faecal calprotectin testing in inflammatory bowel disease: results from a prospective multicentre patient-based survey.

Kalla R, Boyapati R, Vatn S, Hijos G, Crooks B, Moore GT, Hall V, Lipscomb G, Gomollón F, Jahnsen J, Singh S.

Scand J Gastroenterol. 2018 Dec;53(12):1437-1442. doi: 10.1080/00365521.2018.1527394. Epub 2018 Nov 18.

PMID:
30451040
5.

Immunomodulator use does not prevent first loss of response to anti-tumour necrosis factor alpha therapy in inflammatory bowel disease: long-term outcomes in a real-world cohort.

Varma P, Rajadurai AS, Holt DQ, Devonshire DA, Desmond CP, Swan MP, Nathan D, Shelton ET, Prideaux L, Sorrell C, Rusli F, Crantock LRF, Dev A, Ratnam DT, Pianko S, Moore GT.

Intern Med J. 2019 Jun;49(6):753-760. doi: 10.1111/imj.14150.

PMID:
30381884
6.

Crohn's and Colitis Australia Inflammatory Bowel Disease Audit: Identifying disaster in waiting.

Moore GT.

J Gastroenterol Hepatol. 2018 Sep;33 Suppl 3:33-34. doi: 10.1111/jgh.14436. No abstract available.

PMID:
30187565
7.

Let's Provide Primary Care to All Uninsured Americans-Now!

Moore GT.

JAMA. 2018 Jun 5;319(21):2240. doi: 10.1001/jama.2017.12402. No abstract available.

PMID:
29872849
8.

Buruli (Bairnsdale) ulcer in the setting of long-term adalimumab treatment for Crohn disease.

Freckelton J, Holt D, Sandhu M, Prideaux L, Moore GT.

Intern Med J. 2018 May;48(5):603-604. doi: 10.1111/imj.13788. No abstract available.

PMID:
29722190
9.

Predicting response after infliximab salvage in acute severe ulcerative colitis.

Choy MC, Seah D, Gorelik A, An YK, Chen CY, Macrae FA, Sparrow MP, Connell WR, Moore GT, Radford-Smith G, Van Langenberg DR, De Cruz P.

J Gastroenterol Hepatol. 2018 Jul;33(7):1347-1352. doi: 10.1111/jgh.14072. Epub 2018 Feb 27.

PMID:
29266456
10.

Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.

Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, Barclay M, Begun J, Bryant R, Chan W, Corte C, Ghaly S, Lemberg DA, Kariyawasam V, Lewindon P, Martin J, Mountifield R, Radford-Smith G, Slobodian P, Sparrow M, Toong C, van Langenberg D, Ward MG, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group.

Aliment Pharmacol Ther. 2017 Dec;46(11-12):1037-1053. doi: 10.1111/apt.14368. Epub 2017 Oct 13. Review.

11.

Metformin use in diabetics with diverticular disease is associated with reduced incidence of diverticulitis.

Freckelton J, Evans JA, Croagh D, Moore GT.

Scand J Gastroenterol. 2017 Sep;52(9):969-972. doi: 10.1080/00365521.2017.1325930. Epub 2017 May 14.

PMID:
28503973
12.

Editorial: visceral fat as a predictor of post-operative recurrence of Crohn's disease-Authors' reply.

Holt DQ, Moore GT, Strauss BJG, Hamilton AL, De Cruz P, Kamm MA.

Aliment Pharmacol Ther. 2017 Jun;45(12):1552-1553. doi: 10.1111/apt.14102. No abstract available.

13.

Visceral adiposity predicts post-operative Crohn's disease recurrence.

Holt DQ, Moore GT, Strauss BJ, Hamilton AL, De Cruz P, Kamm MA.

Aliment Pharmacol Ther. 2017 May;45(9):1255-1264. doi: 10.1111/apt.14018. Epub 2017 Feb 28.

14.

Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis.

Holt DQ, Varma P, Strauss BJG, Rajadurai AS, Moore GT.

Eur J Clin Nutr. 2017 Jun;71(6):773-777. doi: 10.1038/ejcn.2017.10. Epub 2017 Feb 22.

PMID:
28225051
15.

Weight and Body Composition Compartments do Not Predict Therapeutic Thiopurine Metabolite Levels in Inflammatory Bowel Disease.

Holt DQ, Strauss BJ, Moore GT.

Clin Transl Gastroenterol. 2016 Oct 27;7(10):e199. doi: 10.1038/ctg.2016.56.

16.

Biosimilars in inflammatory bowel disease.

Moore GT.

Med J Aust. 2016 Oct 3;205(7):294-5. No abstract available.

PMID:
27681963
17.

Patients with inflammatory bowel disease and their treating clinicians have different views regarding diet.

Holt DQ, Strauss BJ, Moore GT.

J Hum Nutr Diet. 2017 Feb;30(1):66-72. doi: 10.1111/jhn.12400. Epub 2016 Jul 14.

PMID:
27412965
18.

Review article: acute severe ulcerative colitis - evidence-based consensus statements.

Chen JH, Andrews JM, Kariyawasam V, Moran N, Gounder P, Collins G, Walsh AJ, Connor S, Lee TW, Koh CE, Chang J, Paramsothy S, Tattersall S, Lemberg DA, Radford-Smith G, Lawrance IC, McLachlan A, Moore GT, Corte C, Katelaris P, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group.

Aliment Pharmacol Ther. 2016 Jul;44(2):127-44. doi: 10.1111/apt.13670. Epub 2016 May 26. Review.

19.

Body composition analysis using abdominal scans from routine clinical care in patients with Crohn's Disease.

Holt DQ, Strauss BJ, Lau KK, Moore GT.

Scand J Gastroenterol. 2016 Jul;51(7):842-7. doi: 10.3109/00365521.2016.1161069. Epub 2016 Mar 22.

PMID:
27001198
20.

Achieving and maintaining quality of care in inflammatory bowel disease: The Crohn's and Colitis Australia audit.

Moore GT.

J Gastroenterol Hepatol. 2016 Jun;31 Suppl 1:39. doi: 10.1111/jgh.13367. No abstract available.

PMID:
26992107
21.

Changing face of care for patients with moderate to severe inflammatory bowel disease: the role of specialist nurses in the governance of anti-TNF prescribing.

Connell WR, Samyue T, Gibson PR, Lachal S, Moore GT, Macrae FA, Van Langenberg DR.

Intern Med J. 2015 Nov;45(11):1161-6. doi: 10.1111/imj.12861.

PMID:
26178007
22.

Clinical selection criteria can predict futile intervention in patients referred for percutaneous endoscopic gastrostomy insertion.

Holt DQ, McDonald JF, Murray ML, Hair C, Devonshire DA, Strauss BJ, Moore GT.

Intern Med J. 2015 Jun;45(6):648-52. doi: 10.1111/imj.12705.

PMID:
25644576
23.

Venous thromboembolism and underutilisation of anticoagulant thromboprophylaxis in hospitalised patients with inflammatory bowel disease.

Dwyer JP, Javed A, Hair CS, Moore GT.

Intern Med J. 2014 Aug;44(8):779-84. doi: 10.1111/imj.12488.

PMID:
24893756
24.

Altered glycosylation in donor mice causes rejection of strain-matched skin and heart grafts.

Gock H, Murray-Segal LJ, Winterhalter AC, Aminian A, Moore GT, Brown SJ, d'Apice AJ, Cowan PJ.

Am J Transplant. 2014 Apr;14(4):797-805. doi: 10.1111/ajt.12634. Epub 2014 Feb 6.

25.

Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study.

Gibson PR, Vaizey C, Black CM, Nicholls R, Weston AR, Bampton P, Sparrow M, Lawrance IC, Selby WS, Andrews JM, Walsh AJ, Hetzel DJ, Macrae FA, Moore GT, Weltman MD, Leong RW, Fan T.

J Crohns Colitis. 2014 Jul;8(7):598-606. doi: 10.1016/j.crohns.2013.11.017. Epub 2013 Dec 15.

PMID:
24345767
26.

A theoretical study of transient stimulated Brillouin scattering in optical fibers seeded with phase-modulated light.

Zeringue C, Dajani I, Naderi S, Moore GT, Robin C.

Opt Express. 2012 Sep 10;20(19):21196-213. doi: 10.1364/OE.20.021196.

PMID:
23037244
27.

Primary cytomegalovirus ileitis complicated by massive gastrointestinal haemorrhage in a patient with steroid refractory Crohn's disease.

Le ST, Lee SS, Prideaux L, Block AA, Moore GT.

Intern Med J. 2010 Nov;40(11):788-91. doi: 10.1111/j.1445-5994.2010.02346.x.

PMID:
21155157
28.

Efficacy and safety of single-session argon plasma coagulation in the management of chronic radiation proctitis.

Swan MP, Moore GT, Sievert W, Devonshire DA.

Gastrointest Endosc. 2010 Jul;72(1):150-4. doi: 10.1016/j.gie.2010.01.065. Epub 2010 May 20.

PMID:
20493484
29.

A self-instructional model to teach systems-based practice and practice-based learning and improvement.

Peters AS, Kimura J, Ladden MD, March E, Moore GT.

J Gen Intern Med. 2008 Jul;23(7):931-6. doi: 10.1007/s11606-008-0517-0.

30.

Glycosylation changes in hFUT1 transgenic mice increase TCR signaling and apoptosis resulting in thymocyte maturation arrest.

Moore GT, Brown SJ, Winterhalter AC, Lust M, Salvaris EJ, Selan C, Nandurkar HH, Desmond PV, Cowan PJ, d'Apice AJ.

Mol Immunol. 2008 Apr;45(8):2401-10. Epub 2007 Dec 26.

PMID:
18155296
31.
32.

Educating interprofessional learners for quality, safety and systems improvement.

Ladden MD, Bednash G, Stevens DP, Moore GT.

J Interprof Care. 2006 Oct;20(5):497-505.

PMID:
17000475
33.

Severe recurrent Crohn's disease of the ileocolonic anastomosis disappearing completely with antibacterial therapy.

Elliott PR, Moore GT, Bell SJ, Connell WR.

Gut. 2005 Dec;54(12):1818-9. No abstract available.

34.

Altered immune system glycosylation causes colitis in alpha1,2-fucosyltransferase transgenic mice.

Brown SJ, Miller AM, Cowan PJ, Slavin J, Connell WR, Moore GT, Bell S, Elliott PR, Desmond PV, d'Apice AJ.

Inflamm Bowel Dis. 2004 Sep;10(5):546-56.

PMID:
15472514
35.

Nonresonant recirculating type II second-harmonic generator.

Ross TS, Moore GT.

Appl Opt. 2004 Apr 10;43(11):2353-9.

PMID:
15098839
36.

20 W of continuous-wave sodium D2 resonance radiation from sum-frequency generation with injection-locked lasers.

Bienfang JC, Denman CA, Grime BW, Hillman PD, Moore GT, Telle JM.

Opt Lett. 2003 Nov 15;28(22):2219-21.

PMID:
14649947
37.

Binary coherent beam combination with mirror pairs.

Moore GT.

Appl Opt. 2002 Oct 20;41(30):6399-409.

PMID:
12396192
38.
39.
40.

Long-term outcomes of the New Pathway Program at Harvard Medical School: a randomized controlled trial.

Peters AS, Greenberger-Rosovsky R, Crowder C, Block SD, Moore GT.

Acad Med. 2000 May;75(5):470-9.

PMID:
10824772
41.

Managed care and graduate medical education in the United States.

Simon SR, Moore GT.

Med Educ. 1999 Nov;33(11):797-8. No abstract available.

PMID:
10583784
42.

The clinician-teacher in managed care settings.

Shorey JM, Epstein AL, Moore GT.

J Gen Intern Med. 1997 Apr;12 Suppl 2:S98-103. Review. No abstract available.

43.

Frequency upconversion by phase-matched sum-frequency generation in an optical parametric oscillator.

Cheung EC, Koch K, Moore GT.

Opt Lett. 1994 Dec 1;19(23):1967-9.

PMID:
19855711
44.

The influence of the New Pathway curriculum on Harvard medical students.

Moore GT, Block SD, Style CB, Mitchell R.

Acad Med. 1994 Dec;69(12):983-9.

PMID:
7999195
45.

The physician work force: does the marketplace set national policy?

Fletcher RH, Moore GT.

Ann Intern Med. 1994 Nov 1;121(9):712-3. No abstract available.

PMID:
7944082
46.
47.

Assigning patients according to curriculum: a strategy for improving ambulatory care residency training.

Brush AD, Moore GT.

Acad Med. 1994 Sep;69(9):717-9. No abstract available.

PMID:
8074761
48.

The "teaching HMO": a new academic partner.

Moore GT, Inui TS, Ludden JM, Schoenbaum SC.

Acad Med. 1994 Aug;69(8):595-600.

PMID:
8054102
49.
50.

Measurements of second-order nonlinear optical coefficients from the spectral brightness of parametric fluorescence.

Cheung EC, Koch K, Moore GT, Liu JM.

Opt Lett. 1994 Feb 1;19(3):168. No abstract available.

PMID:
19829580

Supplemental Content

Loading ...
Support Center